We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

2383:TWSEElite Material Co., Ltd. Analysis

Data as of 2026-06-13 - not real-time

NT$4,830.00

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Elite Material Co., Ltd. is riding a strong earnings tide, posting a 52.5% YoY revenue surge and a remarkable 40.7% ROE, while maintaining healthy operating margins above 20%. Technical signals remain bullish—the price (4,830) sits above the 20‑day SMA (4,931) and well above the 50‑day SMA (4,444), with support anchored at 4,300 and resistance near 5,635. However, the MACD histogram is negative and the market is experiencing a 30‑day volatility of roughly 62%, suggesting short‑term price swings. The valuation metrics are stretched; a trailing P/E of 105 dwarfs the industry average of 36, flagging the stock as potentially overvalued despite a modest 8% upside indicated by analyst targets. Dividend sustainability looks acceptable with a 0.34% yield and a payout ratio around 36%, backed by strong operating cash flow, though free cash flow is marginally negative. Overall, the blend of robust fundamentals, elevated valuation, and heightened market volatility points to a cautious but opportunistic stance.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 7/10

Key Factors

  • Price hovering near bullish SMA levels but MACD turning bearish
  • High 30‑day volatility (~62%) could trigger sharp moves
  • Support at 4,300 provides a cushion against downside

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Strong revenue growth (52.5%) and high ROE (40.7%)
  • Analyst consensus of strong‑buy with median target 5,392 (~12% upside)
  • Operating cash flow remains solid despite slight free‑cash‑flow deficit

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Sustained demand for electronic components across multiple high‑tech sectors
  • Robust profitability metrics and manageable debt levels
  • Valuation premium may compress, but growth trajectory supports long‑term upside

Key Metrics & Analysis

Financial Health

Revenue Growth52.50%
Profit Margin15.64%
P/E Ratio105.3
ROE40.68%
ROA12.42%
Debt/Equity52.55
P/B Ratio36.1
Op. Cash FlowNT$12.5B
Free Cash FlowNT$-517416992
Industry P/E36.8

Technical Analysis

TrendBullish
RSI50.9
SupportNT$4,300.00
ResistanceNT$5,635.00
MA 20NT$4,931.00
MA 50NT$4,444.50
MA 200NT$2,334.93
MACDBearish
VolumeStable
Fear & Greed Index89.86

Valuation

Fair ValueNT$878.24
Target PriceNT$5,224.21
Upside/Downside8.16%
GradeOvervalued
TypeGrowth
Dividend Yield0.34%

Risk Assessment

Beta1.26
Volatility61.86%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.